*ST生物：筹划购买慧泽医药51%股权 预计构成重大资产重组

Group 1 - The company *ST Bio (000504) announced on August 11 that it is planning to acquire 51% equity of Hunan Huize Biomedical Technology Co., Ltd. (referred to as "Huize Pharma") in cash [1] - Upon completion of the transaction, Huize Pharma will become a subsidiary controlled by the company [1] - The preliminary assessment indicates that this transaction is expected to constitute a significant asset restructuring [1]